No Data
No Data
Daan Gene: 2024 Semi-Annual Report
Daan Gene: 2024 Semi-Annual Report Summary
daan gene co.,ltd. (002030.SZ): a net loss of 0.399 billion yuan in the first half of the year.
daan gene co.,ltd. (002030.SZ) announced its semi-annual report for the year 2024 on August 30th. During the reporting period, the company achieved revenue of 0.4 billion yuan, a year-on-year decrease of 25.33%. The net income attributable to shareholders of the listed company was -0.399 billion yuan, with a year-on-year change from profit to loss. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.179 billion yuan. The basic earnings per share was -0.28 yuan.
Express News | Daan Gene Says It Swings to Net Loss 399.2 Mln Yuan in H1
Daan Gene Co., Ltd. (002030.SZ): Its wholly-owned subsidiary received cash dividend of 4.1957 million Hong Kong dollars.
On August 28, Gelonhui announced that at the shareholder's annual meeting held by Yuncong Group on June 28, 2024, the proposal to distribute a year-end dividend of HKD 0.02 per share, payable from the company's share premium account, was approved. The company's wholly-owned subsidiary, Da'an International, holds 209,783,000 shares of Yuncong Group, and the cash dividend for this time amounts to HKD 4,195,660.00. Recently, the company's wholly-owned subsidiary, Da'an International, has received the above-mentioned cash dividend payment of HKD 4,195,660.0.
daan gene co.,ltd. (002030.SZ) has obtained two medical instruments registration certificates.
Daan Gene Co., Ltd. (002030.SZ) announced that the company has obtained a medical device registration certificate issued by the National Medical Products Administration...
No Data